NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company earned $19.40 million during the quarter, compared to the consensus estimate of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. The business's revenue for the quarter was down 22.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) EPS. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

2 brokerages have issued 1-year price objectives for Pacific Biosciences of California's stock. Their predictions range from $4.00 to $6.80. On average, they expect Pacific Biosciences of California's stock price to reach $5.40 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price. View Analyst Ratings for Pacific Biosciences of California.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Media coverage about PACB stock has been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a news sentiment score of 0.19 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.59.

Pacific Biosciences of California has a market capitalization of $487.94 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]